Ang X-Y, Chung F-Y-L, Lee B-K, Azhar S N A, Sany S, Roslan N S, Ahmad N, Yusof S M, Abdullah N, Nik Ab Rahman N N, Abdul Wahid N, Deris Z Z, Oon C-E, Wan Adnan W F, Liong M-T
School of Industrial Technology, Universiti Sains Malaysia, Penang, Malaysia.
School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
J Appl Microbiol. 2022 Apr;132(4):3168-3180. doi: 10.1111/jam.15158. Epub 2021 Dec 26.
The aim of this study was to investigate the effects of lactobacilli strains in preventing the recurrences of vaginal candidiasis (VC) in 78 pregnant women with VC (lactobacilli, n = 39; placebo, n = 39) and the potential benefits on quality of life.
The lactobacilli putative probiotic (SynForU-HerCare; two capsules/day of 9·5 log CFU per capsule) or placebo was administered for 8-weeks in a randomized, double-blind, placebo-controlled study. Subjects were assessed for vaginal and gut health conditions at baseline, week-4 and week-8 via questionnaires. The vulvovaginal symptom questionnaire not only covered aspects pertaining to vulvovaginal symptoms but also the quality of life impacts such as emotional, social and sexual. The administration of lactobacilli reduced symptoms of irritation (P = 0·023) and discharge (P = 0·011) starting week-4 and continued after week-8 (P < 0·05), accompanied by reduced symptoms for burning after week-8 (P = 0·046) as compared to the placebo. Patients consuming lactobacilli also showed reduced concern about symptoms after week-4 (P = 0·010) and continued after week-8 (P = 0·001), accompanied by reduced impairment of daily activities attributed to vulvovaginal symptoms (P = 0·012) and continued after week-8 (P = 0·026). Insignificant differences were observed for sexual impacts between treatment groups. The administration of lactobacilli also reduced recurrences of both emotional and social stress as compared to the placebo at both week-4 and week-8 (P < 0·05). Patients consuming lactobacilli showed higher defecation times per week at week-4 (P = 0·010) and week-8 (P = 0·001) as compared to the placebo group, indicating the potential to reduce risks of pregnancy-induced constipation.
Lactobacilli probiotics are beneficial towards pregnant women, especially in reducing vulvovaginal symptoms and recurrences of VC, accompanied by improved emotional and social distress attributed to VC.
The study demonstrated the preventive and modulatory roles of lactobacilli strains against VC in pregnant women. Taken altogether, our present data illustrated that lactobacilli probiotics are beneficial towards pregnant women, especially in reducing vulvovaginal symptoms and recurrences of VC, accompanied by improved emotional and social distress attributed to VC, thus could be a potential strategy for the maintenance of vaginal health during pregnancy.
本研究旨在调查乳酸菌菌株对78例患有阴道念珠菌病（VC）的孕妇预防VC复发的效果（乳酸菌组，n = 39；安慰剂组，n = 39）以及对生活质量的潜在益处。
在一项随机、双盲、安慰剂对照研究中，给予乳酸菌假定益生菌（SynForU-HerCare；每日2粒胶囊，每粒含9.5 log CFU）或安慰剂，持续8周。通过问卷调查在基线、第4周和第8周评估受试者的阴道和肠道健康状况。外阴阴道症状问卷不仅涵盖了与外阴阴道症状相关的方面，还包括对情绪、社交和性等生活质量的影响。从第4周开始，乳酸菌的施用减轻了刺激症状（P = 0.023）和分泌物症状（P = 0.011），并在第8周后持续减轻（P < 0.05），与安慰剂相比，第8周后灼痛症状也减轻（P = 0.046）。服用乳酸菌的患者在第4周后对症状的担忧也减轻（P = 0.010），并在第8周后持续减轻（P = 0.001），同时因外阴阴道症状导致的日常活动受损也减轻（P = 0.012），并在第8周后持续减轻（P = 0.026）。治疗组之间在性方面的影响差异不显著。与安慰剂相比，在第4周和第8周时，乳酸菌的施用也减少了情绪和社交压力的复发（P < 0.05）。与安慰剂组相比，服用乳酸菌的患者在第4周（P = 0.010）和第8周（P = 0.001）每周排便次数更多，表明有可能降低妊娠引起的便秘风险。
乳酸菌益生菌对孕妇有益，特别是在减轻外阴阴道症状和VC复发方面，同时改善了因VC引起的情绪和社交困扰。
该研究证明了乳酸菌菌株对孕妇VC的预防和调节作用。总体而言，我们目前的数据表明，乳酸菌益生菌对孕妇有益，特别是在减轻外阴阴道症状和VC复发方面，同时改善了因VC引起的情绪和社交困扰，因此可能是孕期维持阴道健康的一种潜在策略。
